BACKGROUND AND OBJECTIVE: Bacterial skin and soft tissue infections (SSTI) affect millions of individuals annually in the United States. Treatment of SSTI has been significantly complicated by the increasing emergence of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) strains. The objective of this study was to demonstrate the efficacy of blue light (415 ± 10 nm) therapy for eliminating CA-MRSA infections in skin abrasions of mice. METHODS: The susceptibilities of a CA-MRSA strain (USA300LAC) and human keratinocytes (HaCaT) to blue light inactivation were compared by in vitro culture studies. A mouse model of skin abrasion infection was developed using bioluminescent USA300LAC::lux. Blue light was delivered to the infected mouse skin abrasions at 30 min (acute) and 24 h (established) after the bacterial inoculation. Bioluminescence imaging was used to monitor in real time the extent of infection in mice. RESULTS: USA300LAC was much more susceptible to blue light inactivation than HaCaT cells (p=0.038). Approximately 4.75-log10 bacterial inactivation was achieved after 170 J/cm(2) blue light had been delivered, but only 0.29 log10 loss of viability in HaCaT cells was observed. Transmission electron microscopy imaging of USA300LAC cells exposed to blue light exhibited disruption of the cytoplasmic content, disruption of cell walls, and cell debris. In vivo studies showed that blue light rapidly reduced the bacterial burden in both acute and established CA-MRSA infections. More than 2-log10 reduction of bacterial luminescence in the mouse skin abrasions was achieved when 41.4 (day 0) and 108 J/cm(2) (day 1) blue light had been delivered. Bacterial regrowth was observed in the mouse wounds at 24 h after the blue light therapy. CONCLUSIONS: There exists a therapeutic window of blue light for bacterial infections where bacteria are selectively inactivated by blue light while host tissue cells are preserved. Blue light therapy has the potential to rapidly reduce the bacterial load in SSTI.
BACKGROUND AND OBJECTIVE: Bacterial skin and soft tissue infections (SSTI) affect millions of individuals annually in the United States. Treatment of SSTI has been significantly complicated by the increasing emergence of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) strains. The objective of this study was to demonstrate the efficacy of blue light (415 ± 10 nm) therapy for eliminating CA-MRSA infections in skin abrasions of mice. METHODS: The susceptibilities of a CA-MRSA strain (USA300LAC) and human keratinocytes (HaCaT) to blue light inactivation were compared by in vitro culture studies. A mouse model of skin abrasion infection was developed using bioluminescent USA300LAC::lux. Blue light was delivered to the infected mouse skin abrasions at 30 min (acute) and 24 h (established) after the bacterial inoculation. Bioluminescence imaging was used to monitor in real time the extent of infection in mice. RESULTS: USA300LAC was much more susceptible to blue light inactivation than HaCaT cells (p=0.038). Approximately 4.75-log10 bacterial inactivation was achieved after 170 J/cm(2) blue light had been delivered, but only 0.29 log10 loss of viability in HaCaT cells was observed. Transmission electron microscopy imaging of USA300LAC cells exposed to blue light exhibited disruption of the cytoplasmic content, disruption of cell walls, and cell debris. In vivo studies showed that blue light rapidly reduced the bacterial burden in both acute and established CA-MRSA infections. More than 2-log10 reduction of bacterial luminescence in the mouse skin abrasions was achieved when 41.4 (day 0) and 108 J/cm(2) (day 1) blue light had been delivered. Bacterial regrowth was observed in the mouse wounds at 24 h after the blue light therapy. CONCLUSIONS: There exists a therapeutic window of blue light for bacterial infections where bacteria are selectively inactivated by blue light while host tissue cells are preserved. Blue light therapy has the potential to rapidly reduce the bacterial load in SSTI.
Authors: Chukuka S Enwemeka; Deborah Williams; Steve Hollosi; David Yens; Sombiri K Enwemeka Journal: Lasers Surg Med Date: 2008-12 Impact factor: 4.025
Authors: Marloes M Kleinpenning; Tim Smits; Marjolein H A Frunt; Piet E J van Erp; Peter C M van de Kerkhof; Rianne M J P Gerritsen Journal: Photodermatol Photoimmunol Photomed Date: 2010-02 Impact factor: 3.135
Authors: Yunsong Zhang; Yingbo Zhu; Asheesh Gupta; Yingying Huang; Clinton K Murray; Mark S Vrahas; Margaret E Sherwood; David G Baer; Michael R Hamblin; Tianhong Dai Journal: J Infect Dis Date: 2013-12-30 Impact factor: 5.226
Authors: Sneha S Kelkar; Eleanor McCabe-Lankford; Richard Albright; Phil Harrington; Nicole H Levi-Polyachenko Journal: Lasers Surg Med Date: 2016-09-16 Impact factor: 4.025
Authors: Yunsong Zhang; Yingbo Zhu; Jia Chen; Yucheng Wang; Margaret E Sherwood; Clinton K Murray; Mark S Vrahas; David C Hooper; Michael R Hamblin; Tianhong Dai Journal: Virulence Date: 2016-02-24 Impact factor: 5.882
Authors: Yucheng Wang; Ximing Wu; Jia Chen; Rehab Amin; Min Lu; Brijesh Bhayana; Jie Zhao; Clinton K Murray; Michael R Hamblin; David C Hooper; Tianhong Dai Journal: J Infect Dis Date: 2016-02-17 Impact factor: 5.226
Authors: Adenilson de Souza da Fonseca; Luiz Philippe da Silva Sergio; Andre Luiz Mencalha; Flavia de Paoli Journal: Lasers Med Sci Date: 2021-01-24 Impact factor: 3.161
Authors: Yucheng Wang; Olivia D Harrington; Ying Wang; Clinton K Murray; Michael R Hamblin; Tianhong Dai Journal: J Vis Exp Date: 2017-04-28 Impact factor: 1.355